Jazz Pharmaceuticals (JAZZ) Gross Profit (2010 - 2026)

Jazz Pharmaceuticals' Gross Profit history runs 17 years deep, the most recent figure standing at $934.8 million for Q1 2026.

• In Q1 2026, Gross Profit rose 17.85% year-over-year to $934.8 million; the TTM figure through Mar 2026 stood at $3.9 billion (up 8.2% YoY), while the FY2025 annual figure was $3.8 billion, up 3.89% from the prior year.
• Gross Profit for Q1 2026 stood at $934.8 million, down from $1.0 billion in the prior quarter.
• The five-year high for Gross Profit was $1.0 billion in Q4 2025, with the low at $698.4 million in Q1 2022.
• The 5-year median for Gross Profit is $870.0 million (2023), against an average of $872.9 million.
• The sharpest annual moves came in 2022 and 2025: Gross Profit grew 27.83% in 2022, then decreased 1.65% in 2025.
• Jazz Pharmaceuticals' Gross Profit stood at $804.8 million in 2022, then rose by 12.42% to $904.7 million in 2023, then grew by 6.05% to $959.5 million in 2024, then advanced by 8.85% to $1.0 billion in 2025, then dropped by 10.49% to $934.8 million in 2026.
• Business Quant data shows JAZZ's Gross Profit at $934.8 million in Q1 2026, $1.0 billion in Q4 2025, and $997.2 million in Q3 2025.